Project Title: Evaluation of safety and efficacy of Siphonochilus aethiopicus by using Controlled Human Malaria Infection (CHMI) and Natural malaria infection in adults' volunteers as compared to Artesunate monotherapy
Project Description: The development of insecticide and artemisinin resistance threatens the gains that have been made in the control and elimination of malaria. Insecticide resistance to pyrethroid has been observed in East and Western Africa and the genetic markers of resistance have been reported in many parts of Africa. There are also some reports of a few cases of artemisinin resistance in Africa originating de novo with different mutations compared to South East Asia. However, major efforts... The development of insecticide and artemisinin resistance threatens the gains that have been made in the control and elimination of malaria. Insecticide resistance to pyrethroid has been observed in East and Western Africa and the genetic markers of resistance have been reported in many parts of Africa. There are also some reports of a few cases of artemisinin resistance in Africa originating de novo with different mutations compared to South East Asia. However, major efforts in mapping resistance genotypes have not found to date widespread resistance markers. The project will be divided into two phases: The first phase of the project will assess the safety, tolerability, and parasitic suppression activities of malaria herbal remedy given as preventive or curative medicine among 18 healthy adults aged 18 to 45 years by using Control Human Malaria Infection (CHMI) model. The second phase will be the evaluation of safety, tolerability, pharmacokinetics as well as efficacy of malaria herbal remedy for the treatment of malaria episodes among 104 adults 18 to 45 years with uncomplicated P. falciparum malaria, compared to Artesunate monotherapy in Tanzania.
Principal Investigator : Kamaka Kassim
Department Name : BRCT
Time frame: (2018-09-01) - (2021-09-30)
Rudolf Geigy Foundation (Normal)
External Collaborating Partners
None added yet.